Articles Vol. 63 No. Số tiếng Anh (2022) 08/12/2022

THE RELATIONSHIP BETWEEN PROGNOSTIC FACTORS AND TREATMENT OUTCOME OF MULTIPLE MYELOMA

Phan Nguyen Thanh Van1
1 Pham Ngoc Thach University of Medicine
Corresponding author: pnthanhvan@pnt.edu.vn
DOI: 10.52163/yhc.v63i9.548
10 Views
0 Downloads
Keywords
Multiple myeloma, prognostic factors, relationship.
Abstract

Objectives: To analyze the relationship between prognostic factors to outcomes of
number of multiple myeloma (MM) treatment regimens at Ho Chi Minh city (HCMC)
Blood Transfusion and Hematology Hospital from 2018 to 2021.
Subjects and methods: A descriptive and analytical study on 111 patients newly
diagnosed with MM from January 2018 to December 2021 according to IMWG 2014
standards who came for examination and treatment at HCMC Blood Transfusion and
Hematology Hospital.
Results: The prognostic factors associated with statistical significance to the rate of
at least very good partial response (VGPR) compared with the other group including:
Clinical index ECOG < 2, NLR < 2.25, platelet ≥ 150, novel treatment regimen and
myeloma prognostic index (MPI).
Conclusion: Clinical index ECOG < 2, NLR < 2.25, platelet ≥ 150, new treatment
regimen and MPI were the prognostic factors associated with MM.

References
[1]
O. Landgren. R. A. Kyle. R. M. Pfeiffer. Google Scholar
[2]
et al., Monoclonal gammopathy of Google Scholar
[3]
undetermined significance (MGUS) Google Scholar
[4]
consistently precedes multiple myeloma: Google Scholar
[5]
a prospective study. Blood. 113(22): Google Scholar
[6]
-7, 2009. Google Scholar
[7]
D. A. Goldstein, Denosumab for bone Google Scholar
[8]
lesions in multiple myeloma - what is Google Scholar
[9]
its value? Haematologica. 103(5): 753- Google Scholar
[10]
, 2018. Google Scholar
[11]
N. Tandon. S. Sidana, Outcomes with Google Scholar
[12]
early response to first-line treatment in Google Scholar
[13]
patients with newly diagnosed multiple Google Scholar
[14]
myeloma3(5): 744-750, 2019. Google Scholar
[15]
N. J. Bahlis. A. Corso. L. O. Mugge. Google Scholar
[16]
et al., Benefit of continuous treatment Google Scholar
[17]
for responders with newly diagnosed Google Scholar
[18]
multiple myeloma in the randomized Google Scholar
[19]
FIRST trial. Leukemia. 31(11): 2435- Google Scholar
[20]
, 2017. Google Scholar
[21]
Y. Li. H. Li. W. Li. et al., Pretreatment Google Scholar
[22]
neutrophil/lymphocyte ratio but not Google Scholar
[23]
platelet/lymphocyte ratio has a prognostic Google Scholar
[24]
impact in multiple myeloma. J Clin Lab Google Scholar
[25]
Anal. 31(5), 2017. Google Scholar
[26]
A. J. Templeton. M. G. McNamara. Google Scholar
[27]
B. Seruga et al., Prognostic role of Google Scholar
[28]
neutrophil-to-lymphocyte ratio in solid Google Scholar
[29]
tumors: a systematic review and metaanalysis. J Natl Cancer Inst. 106(6): Google Scholar
[30]
dju124, 2014. Google Scholar
[31]
M. Bakeer. A. C. Zubair. V. Roy, Low Google Scholar
[32]
baseline platelet count predicts poor Google Scholar
[33]
response to plerixafor in patients with Google Scholar
[34]
multiple myeloma undergoing autologous Google Scholar
[35]
stem cell mobilization. Cytotherapy. Google Scholar
[36]
(1): 16-20, 2020. Google Scholar
[37]
Nguyen Thuy Duong, Study clinical Google Scholar
[38]
features. Subclinical and treatment Google Scholar
[39]
results in multiple light chain myeloma Google Scholar
[40]
at the National Institute of Hematology Google Scholar
[41]
and Blood Transfusion. Master thesis in Google Scholar
[42]
medicine, 2018. Google Scholar
[43]
J. F. San Miguel. R. Schlag. N. K. Google Scholar
[44]
Khuageva et al., Bortezomib plus Google Scholar
[45]
melphalan and prednisone for initial Google Scholar
[46]
treatment of multiple myeloma. N Engl J Google Scholar
[47]
Med. 359(9): 906-17, 2008. Google Scholar